Aim: Heterozygous patients with familial hypercholesterolemia (FH) are known to be associated with a high risk of coronary artery disease (CAD), which is a major determinant of their clinical outcome. The prognosis of heterozygous FH patients substantially varies, being dependent on the level of their CAD risk, and their therapeutic regimen should be individualized. We assessed critical levels of LDLcholesterol (LDL-C) and Achilles tendon thickness (ATT) to identify heterozygous FH patients at "very high" risk for CAD. Methods: One hundred and nine heterozygous FH patients who had no history of CAD and had had their plasma lipid profile and ATT assessed before treatment were followed up until their first CAD event or 31 December 2010. Multivariable logistic regression models were used to analyze the correlation of LDL-C and/or ATT levels with the risk of developing CAD. Results: During the follow-up period, 21 of the 109 patients had a CAD event, diagnosed by coronary angiogram. Individuals in the highest tertile of LDL-C had a CAD risk 8.29-fold higher than those in the lowest tertile. Individuals in the highest tertile of the ATT group had a 7.82-fold higher CAD risk than those in the lowest tertile. Those who had either LDL-C ≥ 260 mg/dL or ATT ≥ 14.5 had a 23.94-fold higher CAD risk than those with LDL-C ＜260 mg/dL and ATT ＜14.5 mm. Conclusions: In heterozygous FH patients, LDL-C 260 mg/dL or higher and/or ATT 14.5 mm or thicker are useful markers for extracting patients at "very high" risk for CAD.
Introduction
Familial hypercholesterolemia (FH) is an autosomal dominant disorder characterized by hypercholesterolemia, skin and tendon xanthomas and a high risk of coronary artery disease (CAD) due to premature atherosclerosis 1) . FH has the highest prevalence in genetic metabolic diseases, showing one per 300 to 500 heterozygous patients in the general population 1, 2) . High low-density lipoprotein cholesterol (LDL-C) is the first symptom, appearing in heterozygous FH even from birth, and xanthomas in the Achilles tendon usually appear during or after the late 10s and are found in half of all patients by the age of 30 1) . Coronary artery disease (CAD), which determines the prognosis of FH patients, appears during or after the third decade of life in men and the fifth decade in women [3] [4] [5] .
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Clinical and Laboratory Characteristics
Serum lipid and lipoprotein levels were measured at the time of initial diagnosis, before any lipid-lowering treatment. TC, TG and HDL-C levels were measured enzymatically with a commercial kit (Daiichi Pure Chemicals Co., Tokyo, Japan) using an automated analyzer (Hitachi model 704; Hitachi, Tokyo, Japan) in the clinical laboratory of the National Cerebral and Cardiovascular Center (NCVC). LDL-C was calculated by the Friedewald formula. ATT was measured by X-ray according to the method previously described 13) . Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared (kg/m 2 ). Hypertension was defined as the use of antihypertensive drugs or blood pressure ≥ 140 mmHg systolic or ≥ 90 mmHg diastolic or both at the first clinic visit (the criteria for hypertension of the Japanese Society of Hypertension Guidelines) 14) . Diabetes mellitus was defined according to the 2002 Guideline for the Treatment of Diabetes Mellitus of the Japanese Diabetes Society 15) . A family history of CAD was defined as positive by having within 2nd degree family members with CAD on the standardized questionnaire. Smoking was defined as positive by having a smoking habit at the first visit to NCVC on the patient report.
Statistical Analyses
Continuous variables are presented as the means ±SDs. Categorical data are presented as numbers and percentages. Unpaired Student's t-test and one-way analysis of variance (ANOVA) were used to assess differences between groups in continuous variables. Differences in categorical variables were assessed by the χ 2 test.
Multivariable logistic regression analysis after adjusting for age, sex, hypertension, diabetes mellitus, smoking, family history of CAD, and low HDL-C (＜40 mg/dL) were used to analyze correlations of LDL-C levels or ATT levels and the development of CAD. LDL-C levels were categorized into tertiles: (1) LDL-C ＜206 mg/dL, (2) LDL ≥ 206 and ＜260 mg/ dL, (3) LDL-C ≥ 260 mg/dL. ATT levels were also categorized into tertiles: (1) ATT ＜9.0 mm, (2) ATT ≥ 9.0 mm and ＜14.5 mm, (3) ATT ≥ 14.5 mm. All the confidence intervals were estimated at the 95% level and significance was set at p＜0.05. All data were analyzed with the SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) statistical software package. CAD mortality in heterozygous FH is several times higher than that in the general population 1, [6] [7] [8] ; therefore, it is very important to prevent CAD in heterozygous FH patients. The prognosis of heterozygous patients of FH varies substantially, such that some develop CAD at their 20s while others may not develop CAD until their seventh decade; therefore, the therapeutic regimen should be individualized according to the patients' risk of CAD.
Various risk factors for CAD have been identified in heterozygous patients with FH, such as age, sex, LDL-C, triglyceride (TG), HDL-C, Achilles tendon thickness (ATT), smoking, a family history of CAD, hypertension, diabetes mellitus, Lp(a), homocysteine and so on 3, [9] [10] [11] [12] . Among these parameters, LDL-C and ATT are simple, specific and non-invasive to measure, and can easily be used by primary care physicians to evaluate the CAD risk. We therefore estimated the CAD risks in accordance with LDL-C and ATT in heterozygous FH patients in order to identify those at extremely high risk.
Methods

Subjects
Of the patients referred to the lipid clinic at the National Cerebral and Cardiovascular Center (NCVC) from 1977 to 2007, 329 consecutive patients diagnosed as FH heterozygotes using previously described criteria 6) were subjected to this study. After diagnosis, the FH patients had medical checks according to the standard procedure for treating heterozygous FH in NCVC. The patients were subjected to a treadmill test for CAD screening just after their first visit to our clinic. Those who had a positive result on the treadmill test were subjected to a coronary angiogram (CAG), and diagnosed with CAD with 75% or more stenosis. Those who had a negative result on the treadmill or no significant stenosis by CAG were included in this study. Among the 329 FH patients, 229 were excluded: 53 had a past history of CAD, 160 had not had LDL-C measured before treatment, 76 had not had ATT thickness measured and 3 had TG more than 4.5 mmol/L, so 109 were followed up until their first CAD event or 31 December 2010. After the first visit to our clinic, dietary and drug treatment, including statins, was immediately started and continued.
During the course, those who had chest pain or a positive result on the treadmill test performed biennially were subjected to CAG, and diagnosed with CAD with 75% or more stenosis. Medical records of the patients were examined according to the analysis protocol approved by our institutional ethics committee than TC levels were not significantly different in each tertile. Higher LDL-C was associated with higher TC and the incidence of CAD.
To examine the influence of conventional coronary risk factors, logistic regression analyses for CAD were performed. The multivariable adjusted odds ratios (ORs) for CAD are shown in Table 3 . Individuals in the highest tertile (LDL-C ≥ 260 mg/dL) had a 8.29-fold increased risk of CAD incidence compared with those in the lowest tertile (LDL-C ＜206 mg/dL) (adjusted odds ratio (OR) 8.29, 95 % CI 1.33-51.47, p = 0.023). No significant increase in the odds of future CAD in the second tertile (206≦LDL-C＜260 mg/dL) (adjusted OR 0.42, 95%CI 0.05-3.26, p = 0.409).
Results
Characteristics of the Patients Subjected to Analysis of the Correlations of LDL-C and CAD
Among 109 patients, 21 (19.3%) developed CAD during the subsequent period. There was a significantly higher prevalence of hypertension, skin xanthomas, arcus cornea and smoking in the CAD (＋) group. Mean age, ATT, TC and LDL-C were significantly higher in the CAD (＋) group than in the CAD (−) group ( Table 1) .
LDL-C Levels and Development of CAD
The clinical characteristics of patients categorized into tertiles according to their LDL-C levels are shown in Table 2 . They clearly show that parameters other 20.62-fold increased risk of CAD compared with those with LDL-C ＜260 and ATT ＜14.5 (95%CI 2.91-145.89). Those with either LDL-C ≥ 260 or ATT ≥ 14.5 had a 23.62-fold increased risk of CAD compared with those with LDL-C ＜260 and ATT ＜ 14.5 (95%CI 3.11-184. 16 ).
Discussion
As the prognosis of heterozygous FH patients varies substantially, the therapeutic regimen should be determined according to the CAD risk of individual patients. High levels of LDL-C and ATT are clinical signs already found at a young age and can be measured easily and non-invasively by family physicians in primary care, so they can be good markers for estimating the future CAD risk of FH. In the present study, we demonstrated the critical levels of LDL-C and ATT for estimation of the CAD risk in Japanese heterozygous patients with FH.
Several studies on the Japanese population have indicated that the serum cholesterol level is correlated significantly with the risk of CAD 16, 17) . The increased CAD incidence seems exponential with the serum cholesterol level in the general population, and it can be
ATT Levels and Development of CAD
The clinical characteristics of patients categorized into tertiles according to their ATT levels are shown in Table 4 . Higher ATT levels were associated with higher TC and LDL-C levels, smoking and the incidence of CAD.
The multivariable adjusted OR for CAD is shown in Table 5 . Individuals in the highest tertile group of ATT ≥ 14.5 mm had a 7.82-fold increased risk of CAD compared with those in the ATT ＜9.0 mm group (95%CI 1.28-47.7, p = 0.001). No significant increase in the odds of future CAD in the group with 9≦ATT＜14.5 mm (adjusted OR 1.42, 95%CI 0.18-11.14, p = 0.740).
LDL-C and/or ATT Levels and Development of CAD
To estimate the future risk for CAD using the combination of LDL-C and ATT thickness, the patients were divided into 3 groups, (1) LDL-C ＜260 mg/dL and ATT ＜14.5 mm, (2) LDL-C ＜260 and ATT ≥ 14.5, or LDL-C ≥ 260 and ATT ＜14.5, (3) LDL-C ≥ 260 and ATT ≥ 14.5. OR for CAD was calculated for these groups and shown in Table 6 . Those who had both LDL-C ≥ 260 and ATT ≥ 14.5 had a ment period and CAD risk remained due to pre-exposure to high LDL-C before treatment, although the absolute risk of CAD might be decreased at any LDL-C level by intensive drug treatment during the course. Civerira et al. reported that heterozygous FH with tendon xanthomas has a 3.1-fold increased risk of premature CAD compared with those without it 23) . The Achilles tendon was reported to be thicker in FH patients with CAD than in those without CAD in both sexes 12) . Persistent high LDL-C causes cholesterol depositions in the tendons and results in tendon xanthomas 1) . Achilles tendon xanthomas have been used considered low until it hits a certain "threshold". The findings of the relationship with LDL-C levels and the onset of CAD in FH patients seem to show a "right shift" of this profile as LDL-C 2-fold higher and CAD incidence more than 10-fold. Previous studies have reported that higher LDL-C is related with the higher risk factors for the development of CAD even in heterozygous FH patients 18, 19) , whereas other factors, such as age, gender, hypertension, smoking, or other lipid abnormalities, such as low HDL-C and high TG reportedly contribute to the increased risk 3, 12, [18] [19] [20] [21] [22] . Bujo et al. reported that male gender, age over 50, smoking, hypertension, diabetes mellitus, TG ＞150 mg/dL and HDL-C ＜40 mg/dL were risk factors for CAD in FH by multicenter, cross-sectional analysis 3) .
As we reported in a previous paper, drug treatment including statins may influence the outcome of CAD 5) . The name and dose of drugs prescribed to the patients during the course are listed in Table 7 . Because all FH patients had had intensive drug therapy to prevent the development of atherosclerosis, no comparison could be made with those without drug therapy. It was also impossible to analyze the difference in drugs statistically because there were so many patterns of prescription and most patients changed the type and dose of drugs several times during the course.
LDL-C levels under drug treatment may also affect the outcome. The mean LDL-C under drug treatment did not increase the odds ratio for CAD (odds ratio: 0.983, 95%CI: 0.97-1.00); however the relationship between mean LDL-C in the pre-treat- as one of the criteria for clinical diagnosis of FH because of their high sensitivity and specificity 1, 24) . A strongly positive correlation was observed between ATT and cholesterol-year scores in FH patients 25, 26) , suggesting that ATT reflects both the severity and duration of hypercholesterolemia. ATT is an important factor that can be measured quantitatively as the deposition of cholesterol in the tissue. The present study showed that ATT is a good marker for evaluating the risk for CAD, indicating that there is a strong correlation between the deposition of cholesterol in extravascular tissue and the stenosis of coronary arteries. ATT should be used not only as a diagnostic parameter for FH but also, and more importantly, as a prognostic factor that indicates the need for a more aggressive approach for patients at high risk.
In conclusion, LDL-C ≥ 260 mg/dL and ATT ≧14.5 mm or thicker are useful criteria for identifying patients at "very high" risk of CAD in Japanese heterozygous FH. Patients with either of these risk factors require more intensive cholesterol-lowering therapy and a more careful medical check-up for CAD.
